(Q36407425)

14 August 2017

1 reference

title

Emerging Flt3 kinase inhibitors in the treatment of leukaemia (English)

1 reference

14 August 2017

1 reference

2

Carsten Müller-Tidow

0 references

author name string

Lara Tickenbrock

series ordinal

1

1 reference

14 August 2017

Wolfgang E Berdel

series ordinal

3

1 reference

14 August 2017

Hubert Serve

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

153-165

1 reference

14 August 2017

cites work

Focus on acute leukemias

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Flt3 receptor tyrosine kinase as a drug target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3 mutations in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Switching signals on or off by receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Signal transducer and activator of transcription proteins in leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

The importance of PU.1 concentration in hematopoietic lineage commitment and maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A role for Wnt signalling in self-renewal of haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Effect of herbimycin A on tyrosine kinase receptors and platelet derived growth factor (PDGF)-induced signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

Stat5 tetramer formation is associated with leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.153

10.1517/14728214.11.1.153

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference